Sumatriptan

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
All congenital malformations (majors, minors, majors and minors, or unspecified)1.00 [0.87, 1.14]0%5 studies57,0074,840not evaluable
Major congenital malformations1.07 [0.39, 2.88]25%4 studies1222,583not evaluable
8 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
preterm (< 37 weeks)1.60 [0.43, 5.97]79%3 studies103691not evaluable
low birth weight (< 2500g)0.92 [0.64, 1.33]0%3 studies801,267not evaluable
2 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
Postpartum hemorrhage0.49 [0.25, 0.96]-1 study82104not evaluable
1 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
1 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
Early intrauterine death (< 22 weeks)1.06 [0.68, 1.67]26%4 studies7354,196not evaluable
Elective termination of pregnancy1.02 [0.50, 2.05]0%3 studies1624,198not evaluable
Late intrauterine deaths (> 22 weeks)0.91 [0.16, 5.06]0%3 studies204,198not evaluable
2 non statistically significant endpoints reported in only one study